Exelixis Inc. (NASDAQ:EXEL) shares were down 0.1% during mid-day trading on Friday . The company traded as low as $7.95 and last traded at $8.15, with a volume of 7,419,874 shares changing hands. The stock had previously closed at $8.14.

A number of research analysts recently issued reports on EXEL shares. Stifel Nicolaus upgraded Exelixis from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Monday, April 4th. Cowen and Company reiterated a “buy” rating on shares of Exelixis in a research report on Tuesday, May 24th. Finally, Leerink Swann reiterated a “buy” rating and set a $8.00 price target (up previously from $7.00) on shares of Exelixis in a research report on Thursday, May 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $7.63.

The firm’s market capitalization is $1.86 billion. The stock has a 50-day moving average price of $7.26 and a 200 day moving average price of $5.15.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.02. During the same period in the previous year, the company earned ($0.18) earnings per share. The company earned $15.40 million during the quarter, compared to analyst estimates of $9.11 million. The business’s revenue was up 63.8% compared to the same quarter last year. Equities research analysts expect that Exelixis Inc. will post ($0.83) earnings per share for the current fiscal year.

In other Exelixis news, Director Lance Willsey acquired 40,000 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The stock was acquired at an average price of $4.97 per share, with a total value of $198,800.00. Following the transaction, the director now owns 548,273 shares of the company’s stock, valued at $2,724,916.81. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Several institutional investors have bought and sold shares of EXEL. ProShare Advisors LLC boosted its position in Exelixis by 11.4% in the fourth quarter. ProShare Advisors LLC now owns 215,541 shares of the biotechnology company’s stock valued at $1,216,000 after buying an additional 22,096 shares in the last quarter. California State Teachers Retirement System boosted its position in Exelixis by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 417,800 shares of the biotechnology company’s stock valued at $2,356,000 after buying an additional 6,682 shares in the last quarter. Finally, Tekla Capital Management LLC acquired a new position in Exelixis during the fourth quarter valued at $5,775,000.

Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.